Phase II, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma with or without Prior Exposure to a BTK Inhibitor November 21, 2017 Type of Cancer Hematological Malignancies Sponsor Incyte Protocol Number INCB 50465-204 To Learn More Call (201)-510-0950
